These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Clinical trials with Pseudomonas exotoxin immunotoxins. Pai LH; Pastan I Curr Top Microbiol Immunol; 1998; 234():83-96. PubMed ID: 9670614 [No Abstract] [Full Text] [Related]
25. A magic bullet for cancer--how near and how far? Schnipper LE; Strom TB N Engl J Med; 2001 Jul; 345(4):283-4. PubMed ID: 11474668 [No Abstract] [Full Text] [Related]
26. [Protein engineering of Pseudomonas exotoxin and its targeting therapy of cancer]. Kondo T Tanpakushitsu Kakusan Koso; 1989 Oct; 34(13):1793-803. PubMed ID: 2513619 [No Abstract] [Full Text] [Related]
27. Recent development and optimization of pseudomonas aeruginosa exotoxin immunotoxins in cancer therapeutic applications. Wu T; Zhu J Int Immunopharmacol; 2021 Jul; 96():107759. PubMed ID: 34162138 [TBL] [Abstract][Full Text] [Related]
28. [Recombinant immunotoxins and chimeric toxins for targeted therapy in oncology]. Chiron MF Bull Cancer; 1997 Dec; 84(12):1135-40. PubMed ID: 9587366 [TBL] [Abstract][Full Text] [Related]
29. General strategies in in vivo animal modeling. Vallera DA; Blazar BR Targeted Diagn Ther; 1992; 7():63-77. PubMed ID: 1633310 [No Abstract] [Full Text] [Related]
31. New insights on Morgan RN; Saleh SE; Farrag HA; Aboshanab KM Ther Deliv; 2023 Jan; 14(1):31-60. PubMed ID: 36950853 [TBL] [Abstract][Full Text] [Related]
32. Recombinant antibody fragments and immunotoxin fusions for cancer therapy. Brinkmann U In Vivo; 2000; 14(1):21-7. PubMed ID: 10757057 [TBL] [Abstract][Full Text] [Related]